PART B - FEE(S) TRANSMITTAL

Complete and send this form, together with applicable fee(s), to: Mail Mail Stop ISSUE FEE Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 or Fax (571) 273-2885

ISSUE FEE

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where appropriate. All furtile correspondence including the Faters, dataence orders and notification of maintenance fees will be mainted to the current correspondence address or address or address or address of directed otherwise in Block 1, by (a) specifying a new correspondence address; under (b) indicating a separate FEE ADDRESS* for maintenance fee notifications

CURRENT CORRESPONDENCE ADORESS (Note: Use Block 1 for any change of address)

35969 Barbara A. Shimei Director, Patents & Licensing Bayer HealthCare LLC - Pharmaceuticals 555 White Plains Road, Third Floor Tarrytown, NY 10591

Note: A certificate of mailing can only be used for domestic mailings of the Feetys Transmittat. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission

Certificate of Mailing or Transmission

TOTAL FEE(S) DUE

3 Karen B. King

DATE DUE

I hereby certify that this Feets) Transmittat is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being facsimile transmitted to the USPTO (571) 273-2883, on the date indicated below.

(Deposition's page (Stenatur (Cate

APPLICATION NO FILING DATE FIRST NAMED INVENTOR ATTORNEY DOCKET NO. CONFIRMATION NO. 10/590 770 06/18/2007 Heike Gielen-Haertwig RHC 041036 2475

TITLE OF INVENTION:

APPLN, TYPE

	nonprovisional	NO	\$1740)	\$300	\$2	040	12/15/2011	
	EXAMINER		ARTUN	TΤ	CLASS-SUBCLASS				
Change of correspondence address or indication of "Fee Address" (37 CFR 1.363).			2. For printing on the patent front page, list			, Jonathan R. Harris			
	Change of correspondence address (or Change of Correspondence		 the names of up to 3 registered patent attorneys or agents OR, alternatively, 		attorneys	The same O. Blanding I in			
	Address form PTO/SB/122) attached.			(2) the news of a single firm (basing as a member a			2 Thomas C. Blankinship		

PUBLICATION FEE

(2) the name of a single firm (having as a member a

registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name is listed, no name will be printed. Number is required. 3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)

PLEASE NOTE. Unless an assignee is identified below, no assignee data will appear on the parent. If an assignee is identified below, the document has been filed for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment.

(A) NAME OF ASSIGNEE (B) RESIDENCE: (CITY and STATE OR COUNTRY)

BAYER PHARMA AKTIENGESELLSCHAFT Berlin, Germany

☐ "Fee Address" indication (or "Fee Address" Indication form PTO/SB/47; Rev 03-02 or more recent) attached. Use of a Customer

SMALL ENTITY

ease check the appropriate assignee category or categori	es (will not be printed on the patent) :	☐ Individual	Corporation or other private group entity	Governmen
. The following fee(s) are enclosed:	4b. Payment of Fee(s):			

Issue Fee A check in the amount of the fee(s) is enclosed

Publication Fee (No small entity discount permitted) Payment by credit card. Form PTO-2038 is attached. Advance Order - # of Copies

The Director is hereby authorized by charge the required fee(s), or credit any overpayment, to Denosit Account Number 133372

5. Change in Entity Status (from status indicated above)

a. Applicant claims SMALL ENTITY status. See 37 CFR 1.27. b. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2).

The Director of the USPTO is requested to apply the Issue Fee and Publication Fee (if any) or to re-apply any previously paid issue Fee to the application identified above. NOTE: The Issue Fee and Publication Fee (if recuired) will not be accepted from anyone other than the applicant; a registered attorney or agent; or the assignee or other party in miterest as shown by the records of the United States Patent and Trademark Office.

Authorized Signature /KAREN B. KING/ Date 2011-12-08

Typed or printed name Karen B. King Registration No. 41898

This collection of information is required by 37 CFR 1.311. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) axis oursection or automation is required by 5 of CFR 1,311, 1 or information is required to obtain or relain a benefit by the public which is to file (and by the USPTO to process) an application. Cindificatiality is governed by 35 USC, 122 and 37 CFR 1,41. This collection is estimated to take 12 initiates to complete, including gatherials, including subsequent, perspang, assumitting the completed application form to the USFTO in well viary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing thes butters, should be set to the Chri Information Officer, U.S. Patertament (V.S. Papertament C.C. Osmerece, P.O. Box 1450, Alexandria, Virginia 22313-1450, DO NOT SIXD FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22315-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the
 Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C 552a). Records from
 this system of records may be disclosed to the Department of Justice to determine whether
 disclosure of these records is required by the Freedom of Information Act.
- A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
- A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
- A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
- A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.